Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
In patients with fibromyalgia syndrome (FMS) and temporomandibular disorder (TMD), stress and pain may chronically enhance sympathetic activity, altering cardiovascular responses and worsening pain. This study examined cardiovascular, epinephrine (EPI), norepinephrine (NE), cortisol and clinical pain responses in 54 female patients with these disorders and 34 controls. In a subsample of 10 FMS, 10 TMD patients and 16 controls, using a counterbalanced, double-blind, crossover design, the same responses were assessed after intravenous administration of low dose propranolol vs placebo. Testing included baseline, postural, speech and ischemic pain stressors. FMS patients showed lesser heart rate (HR) increases to posture challenge but greater blood pressure (BP) increases to postural and speech tasks than controls, as well as higher overall BP and greater total vascular resistance (TVR) than TMDs or controls. TMDs showed higher overall cardiac output and lower TVR than controls. Both FMS and TMD groups showed lower baseline NE than controls, and TMDs showed lower overall EPI and NE levels. Group differences in HR, EPI and NE were abolished after propranolol although BP, CO and TVR differences persisted. In both FMS and TMD, the number of painful body sites and ratings of total clinical pain obtained 4 times during each session were significantly lower after beta-blockade vs placebo.


CONCLUSIONS
These findings support the hypothesis that both FMS and TMD may frequently involve dysregulation of beta-adrenergic activity that contributes to altered cardiovascular and catecholamine responses and to severity of clinical pain. Acute treatment with low-dose propranolol led to short-term improvement in all these domains.
Health Sciences Center, University of Utah, Salt Lake City, Utah, USA. Kathleen.C.Light@hsc.utah.edu
Kathleen C
KC
Light
Edith E
EE
Bragdon
Karen M
KM
Grewen
Kimberly A
KA
Brownley
Susan S
SS
Girdler
William
W
Maixner
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004837:Epinephrine / Q000097:blood; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy / Q000503:physiopathology*; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D010146:Pain / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D010147:Pain Measurement; D011187:Posture / Q000502:physiology; D011433:Propranolol / Q000627:therapeutic use; D013315:Stress, Psychological / Q000503:physiopathology / Q000523:psychology; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D013705:Temporomandibular Joint Disorders / Q000188:drug therapy / Q000503:physiopathology*
D000319:Adrenergic beta-Antagonists; D011433:Propranolol; D006854:Hydrocortisone; D009638:Norepinephrine; D004837:Epinephrine